VYNE Therapeutics Inc. (VYNE)
Company Description
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions.
The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis.
It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.
The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020.
VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
| Country | United States |
| IPO Date | Jan 25, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | David T. Domzalski |
Contact Details
Address: 520 U.S. Highway 22 Bridgewater, New Jersey United States | |
| Website | https://www.vynetherapeutics.com |
Stock Details
| Ticker Symbol | VYNE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001566044 |
| CUSIP Number | 92941V209 |
| ISIN Number | US92941V3087 |
| Employer ID | 45-3757789 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David T. Domzalski | Chief Executive Officer, President & Director |
| Mutya Harsch J.D. | General Counsel, Chief Legal Officer & Company Secretary |
| Tyler Zeronda CPA | Chief Financial Officer & Treasurer |
| Dr. Darrell S. Rigel FAAD, M.D. | Consultant |
| Dr. Iain A. Stuart Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 02, 2025 | 4 | Filing |
| Apr 02, 2025 | 4 | Filing |
| Apr 02, 2025 | 4 | Filing |
| Apr 02, 2025 | 4 | Filing |
| Mar 06, 2025 | 10-K | Annual Report |
| Mar 06, 2025 | 8-K | Current Report |
| Jan 23, 2025 | 4 | Filing |
| Jan 23, 2025 | 4 | Filing |
| Jan 23, 2025 | 4 | Filing |
| Jan 23, 2025 | 4 | Filing |